Christopher W. Ogden's most recent trade in CytomX Therapeutics Inc was a trade of 37,500 Performance Stock Units done . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2025 | 37,500 | 0 | - | - | Performance Stock Units | |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2025 | 37,500 | 236,885 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.69 per share. | 13 Jun 2025 | 10,614 | 226,271 (0%) | 0% | 2.7 | 28,540 | Common Stock |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.95 per share. | 13 Jun 2025 | 1,641 | 199,385 (0%) | 0% | 3.0 | 4,841 | Common Stock |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.60 per share. | 18 Mar 2025 | 8,551 | 201,026 (0%) | 0% | 0.6 | 5,122 | Common Stock |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 57,500 | 209,577 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 44,000 | 152,077 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2024 | 6,875 | 110,061 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2024 | 6,875 | 0 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.23 per share. | 20 Aug 2024 | 1,984 | 108,077 (0%) | 0% | 1.2 | 2,439 | Common Stock |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Christopher W. Ogden | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 17,500 | 103,186 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Christopher W. Ogden | SVP, Finance and Accounting | Sale of securities on an exchange or to another person at price $ 2.09 per share. | 19 Mar 2024 | 2,971 | 85,686 (0%) | 0% | 2.1 | 6,196 | Common Stock |
| CytomX Therapeutics Inc | Christopher Ogden W. | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 154,000 | 154,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Christopher W. Ogden | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 75,000 | 75,000 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | W. Christopher Ogden | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 40,000 | 88,657 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Ogden W. Christopher | SVP, Finance and Accounting | Sale of securities on an exchange or to another person at price $ 1.38 per share. | 20 Dec 2023 | 1,990 | 48,657 (0%) | 0% | 1.4 | 2,747 | Common Stock |
| CytomX Therapeutics Inc | W. Christopher Ogden | SVP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2023 | 6,875 | 6,875 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | W. Christopher Ogden | SVP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2023 | 6,875 | 50,647 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Christopher W. Ogden | SVP, Finance and Accounting | Sale of securities on an exchange or to another person at price $ 1.98 per share. | 16 Mar 2023 | 516 | 37,772 (0%) | 0% | 2.0 | 1,021 | Common Stock |
| CytomX Therapeutics Inc | Christopher W. Ogden | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Christopher W. Ogden | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 75,000 | 75,000 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | Christopher W. Ogden | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 25,000 | 38,288 (0%) | 0% | 0 | Common Stock |